Full house nephropathy with normal range serologic markers – a case report
Lusiadas Scientific Journal · 05.07.2022
DOI: 10.48687/lsj.116 ↗Kurz gefasst
Fallbericht in der Zeitschrift Lusiadas Scientific Journal, erschienen am 05.07.2022. Verfasst von Garrido und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Full-house immunofluorescence pattern is most commonly a presentation of Lupus Nephritis. In the absence of characteristic serologic markers, determines a rare diagnostic and therapeutic challenge. A fourteen-year-old female adolescent with sickle cell disease presented with nephrotic syndrome, pneumonia, empyema and arterial hypertension. The histopathology examination of kidney biopsy revealed a proliferative glomerulonephritis with a full-house pattern. Autoantibodies were negative, no complement consumption was detected and direct Coombs’ test was unremarkable. Other possible etiologies were ruled out. Remission was achieved with high dose corticosteroids and mycophenolate mofetil. All other Systemic Lupus Erythematosus clinical and laboratory criteria remained negative during the follow-up. This case report aims to contribute to the awareness of a rare clinical entity, emphasizing the necessity of a correct treatment and a regular long-term follow-up.
Schlagwörter
Zitieren
APA
Garrido, André, Martins, Andreia, Manso, Rita, Cabral, Marta, Loureiro, & Helena (2022). Full house nephropathy with normal range serologic markers – a case report. Lusiadas Scientific Journal. https://doi.org/10.48687/lsj.116
Vancouver
Garrido, André, Martins, Andreia, Manso, Rita, et al. Full house nephropathy with normal range serologic markers – a case report. Lusiadas Scientific Journal. 2022. doi:10.48687/lsj.116
BibTeX
@article{Garrido2022,
author = {Garrido and André and Martins and Andreia and Manso and Rita and Cabral and Marta and Loureiro and Helena},
title = {Full house nephropathy with normal range serologic markers – a case report},
journal = {Lusiadas Scientific Journal},
year = {2022},
doi = {10.48687/lsj.116}
}
EUVIMED